Annual EBITDA
$4.69 B
-$566.30 M-10.77%
31 December 2023
Summary:
Regeneron Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently $4.69 billion, with the most recent change of -$566.30 million (-10.77%) on 31 December 2023. During the last 3 years, it has risen by +$590.10 million (+14.38%). REGN annual EBITDA is now -51.46% below its all-time high of $9.67 billion, reached on 31 December 2021.REGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$1.63 B
-$135.10 M-7.66%
30 September 2024
Summary:
Regeneron Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $1.63 billion, with the most recent change of -$135.10 million (-7.66%) on 30 September 2024. Over the past year, it has increased by +$394.50 million (+31.97%). REGN quarterly EBITDA is now -57.57% below its all-time high of $3.84 billion, reached on 30 June 2021.REGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$5.50 B
+$394.50 M+7.72%
30 September 2024
Summary:
Regeneron Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $5.50 billion, with the most recent change of +$394.50 million (+7.72%) on 30 September 2024. Over the past year, it has increased by +$645.30 million (+13.29%). REGN TTM EBITDA is now -43.10% below its all-time high of $9.67 billion, reached on 31 December 2021.REGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
REGN EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.8% | +32.0% | +13.3% |
| 3 y3 years | +14.4% | -14.5% | -34.3% |
| 5 y5 years | +71.9% | +96.4% | +125.0% |
REGN EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -51.5% | +14.4% | -37.2% | +96.0% | -43.1% | +21.0% |
| 5 y | 5 years | -51.5% | +75.8% | -57.6% | +122.8% | -43.1% | +125.0% |
| alltime | all time | -51.5% | +2852.2% | -57.6% | +3267.1% | -43.1% | +3326.4% |
Regeneron Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.63 B(-7.7%) | $5.50 B(+7.7%) |
| June 2024 | - | $1.76 B(+112.3%) | $5.11 B(+12.3%) |
| Mar 2024 | - | $830.90 M(-35.0%) | $4.55 B(-3.1%) |
| Dec 2023 | $4.69 B(-10.8%) | $1.28 B(+3.6%) | $4.69 B(-3.4%) |
| Sept 2023 | - | $1.23 B(+2.4%) | $4.86 B(-7.3%) |
| June 2023 | - | $1.20 B(+23.5%) | $5.24 B(+3.0%) |
| Mar 2023 | - | $975.50 M(-32.4%) | $5.09 B(-3.3%) |
| Dec 2022 | $5.26 B(-45.6%) | $1.44 B(-10.8%) | $5.26 B(-17.9%) |
| Sept 2022 | - | $1.62 B(+54.0%) | $6.41 B(-4.3%) |
| June 2022 | - | $1.05 B(-8.6%) | $6.70 B(-29.4%) |
| Mar 2022 | - | $1.15 B(-55.7%) | $9.48 B(-1.9%) |
| Dec 2021 | $9.67 B(+135.7%) | $2.59 B(+36.1%) | $9.67 B(+15.4%) |
| Sept 2021 | - | $1.90 B(-50.4%) | $8.38 B(+10.9%) |
| June 2021 | - | $3.84 B(+187.5%) | $7.56 B(+60.6%) |
| Mar 2021 | - | $1.33 B(+2.6%) | $4.71 B(+14.7%) |
| Dec 2020 | $4.10 B(+53.7%) | $1.30 B(+20.0%) | $4.10 B(+9.3%) |
| Sept 2020 | - | $1.08 B(+9.8%) | $3.75 B(+7.3%) |
| June 2020 | - | $987.40 M(+35.1%) | $3.50 B(+25.1%) |
| Mar 2020 | - | $730.80 M(-23.1%) | $2.80 B(+4.7%) |
| Dec 2019 | $2.67 B(-2.2%) | $950.80 M(+14.7%) | $2.67 B(+9.2%) |
| Sept 2019 | - | $829.20 M(+191.2%) | $2.45 B(+6.6%) |
| June 2019 | - | $284.80 M(-52.9%) | $2.29 B(-15.2%) |
| Mar 2019 | - | $604.80 M(-16.7%) | $2.71 B(-0.9%) |
| Dec 2018 | $2.73 B(+21.4%) | $726.40 M(+7.0%) | $2.73 B(+5.0%) |
| Sept 2018 | - | $678.70 M(-2.6%) | $2.60 B(+2.7%) |
| June 2018 | - | $696.60 M(+10.9%) | $2.53 B(+5.4%) |
| Mar 2018 | - | $628.20 M(+5.5%) | $2.40 B(+6.7%) |
| Dec 2017 | $2.25 B(+56.0%) | $595.31 M(-2.3%) | $2.25 B(+11.0%) |
| Sept 2017 | - | $609.51 M(+7.6%) | $2.03 B(+11.9%) |
| June 2017 | - | $566.38 M(+18.5%) | $1.81 B(+15.8%) |
| Mar 2017 | - | $477.90 M(+28.1%) | $1.56 B(+8.5%) |
| Dec 2016 | $1.44 B(+9.7%) | $373.18 M(-5.3%) | $1.44 B(+10.4%) |
| Sept 2016 | - | $394.22 M(+23.8%) | $1.31 B(-1.6%) |
| June 2016 | - | $318.54 M(-10.5%) | $1.33 B(-3.2%) |
| Mar 2016 | - | $355.77 M(+49.8%) | $1.37 B(+4.3%) |
| Dec 2015 | $1.31 B(+54.4%) | $237.44 M(-42.8%) | $1.31 B(+2.1%) |
| Sept 2015 | - | $415.24 M(+14.8%) | $1.29 B(+19.5%) |
| June 2015 | - | $361.81 M(+20.7%) | $1.08 B(+13.7%) |
| Mar 2015 | - | $299.76 M(+42.6%) | $947.02 M(+11.2%) |
| Dec 2014 | $851.29 M(+8.6%) | $210.21 M(+2.5%) | $851.29 M(+0.7%) |
| Sept 2014 | - | $205.06 M(-11.6%) | $845.21 M(-4.9%) |
| June 2014 | - | $232.00 M(+13.7%) | $888.38 M(+7.7%) |
| Mar 2014 | - | $204.03 M(-0.0%) | $825.14 M(+5.2%) |
| Dec 2013 | $784.02 M(+57.9%) | $204.13 M(-17.8%) | $784.02 M(+6.6%) |
| Sept 2013 | - | $248.22 M(+47.1%) | $735.73 M(+5.1%) |
| June 2013 | - | $168.76 M(+3.6%) | $699.71 M(+11.4%) |
| Mar 2013 | - | $162.91 M(+4.5%) | $628.35 M(+26.5%) |
| Dec 2012 | $496.67 M(-391.3%) | $155.83 M(-26.6%) | $496.67 M(+63.3%) |
| Sept 2012 | - | $212.21 M(+117.9%) | $304.16 M(+616.0%) |
| June 2012 | - | $97.40 M(+211.9%) | $42.48 M(-139.9%) |
| Mar 2012 | - | $31.23 M(-185.1%) | -$106.33 M(-37.6%) |
| Dec 2011 | -$170.53 M(+125.4%) | -$36.68 M(-25.9%) | -$170.53 M(+21.9%) |
| Sept 2011 | - | -$49.47 M(-3.8%) | -$139.90 M(+19.4%) |
| June 2011 | - | -$51.42 M(+56.0%) | -$117.19 M(+38.9%) |
| Mar 2011 | - | -$32.97 M(+444.6%) | -$84.37 M(+11.5%) |
| Dec 2010 | -$75.66 M(+36.7%) | -$6.05 M(-77.4%) | -$75.66 M(-24.0%) |
| Sept 2010 | - | -$26.75 M(+43.7%) | -$99.59 M(+41.2%) |
| June 2010 | - | -$18.61 M(-23.3%) | -$70.55 M(+8.2%) |
| Mar 2010 | - | -$24.25 M(-19.1%) | -$65.21 M(+21.6%) |
| Dec 2009 | -$55.37 M(-4.1%) | -$29.98 M(-1404.3%) | -$53.62 M(+54.1%) |
| Sept 2009 | - | $2.30 M(-117.3%) | -$34.80 M(-35.9%) |
| June 2009 | - | -$13.27 M(+4.8%) | -$54.26 M(-5.9%) |
| Mar 2009 | - | -$12.66 M(+13.4%) | -$57.67 M(-0.5%) |
| Dec 2008 | -$57.74 M(-29.6%) | -$11.17 M(-34.9%) | -$57.97 M(+67.8%) |
| Sept 2008 | - | -$17.16 M(+2.9%) | -$34.54 M(-35.1%) |
| June 2008 | - | -$16.68 M(+28.6%) | -$53.19 M(-17.2%) |
| Mar 2008 | - | -$12.96 M(-205.7%) | -$64.24 M(-21.7%) |
| Dec 2007 | -$82.07 M | $12.26 M(-134.2%) | -$82.07 M(-34.0%) |
| Sept 2007 | - | -$35.81 M(+29.1%) | -$124.42 M(+9.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2007 | - | -$27.73 M(-9.9%) | -$113.16 M(+6.8%) |
| Mar 2007 | - | -$30.79 M(+2.3%) | -$105.99 M(+13.9%) |
| Dec 2006 | -$93.06 M(-166.5%) | -$30.09 M(+22.6%) | -$93.06 M(-158.1%) |
| Sept 2006 | - | -$24.55 M(+19.4%) | $160.22 M(+3.8%) |
| June 2006 | - | -$20.56 M(+15.1%) | $154.32 M(+5.3%) |
| Mar 2006 | - | -$17.86 M(-108.0%) | $146.54 M(+4.7%) |
| Dec 2005 | $139.93 M(+566.1%) | $223.19 M(-832.9%) | $139.93 M(-285.6%) |
| Sept 2005 | - | -$30.45 M(+7.5%) | -$75.38 M(+49.2%) |
| June 2005 | - | -$28.34 M(+15.7%) | -$50.53 M(+62.8%) |
| Mar 2005 | - | -$24.48 M(-410.3%) | -$31.04 M(-247.8%) |
| Dec 2004 | $21.01 M(-124.1%) | $7.89 M(-240.8%) | $21.01 M(+7070.0%) |
| Sept 2004 | - | -$5.60 M(-36.7%) | $293.00 K(-101.8%) |
| June 2004 | - | -$8.85 M(-132.1%) | -$16.15 M(-51.3%) |
| Mar 2004 | - | $27.57 M(-314.9%) | -$33.18 M(-61.8%) |
| Dec 2003 | -$87.05 M(-23.3%) | -$12.82 M(-41.8%) | -$86.84 M(-18.5%) |
| Sept 2003 | - | -$22.05 M(-14.8%) | -$106.60 M(-6.9%) |
| June 2003 | - | -$25.88 M(-0.8%) | -$114.56 M(-1.6%) |
| Mar 2003 | - | -$26.09 M(-19.9%) | -$116.40 M(+2.6%) |
| Dec 2002 | -$113.50 M(+42.6%) | -$32.58 M(+8.6%) | -$113.50 M(+4.4%) |
| Sept 2002 | - | -$30.01 M(+8.2%) | -$108.70 M(+8.2%) |
| June 2002 | - | -$27.72 M(+19.6%) | -$100.47 M(+12.4%) |
| Mar 2002 | - | -$23.18 M(-16.5%) | -$89.41 M(+12.3%) |
| Dec 2001 | -$79.61 M(+281.7%) | -$27.78 M(+27.6%) | -$79.61 M(+32.0%) |
| Sept 2001 | - | -$21.77 M(+30.7%) | -$60.32 M(+14.1%) |
| June 2001 | - | -$16.67 M(+24.5%) | -$52.87 M(+35.4%) |
| Mar 2001 | - | -$13.38 M(+57.6%) | -$39.05 M(+17.5%) |
| Dec 2000 | -$20.86 M(+2.2%) | -$8.49 M(-40.7%) | -$33.22 M(+35.4%) |
| Sept 2000 | - | -$14.33 M(+405.2%) | -$24.52 M(+70.4%) |
| June 2000 | - | -$2.84 M(-62.4%) | -$14.39 M(-24.5%) |
| Mar 2000 | - | -$7.55 M(-3877.0%) | -$19.05 M(-10.1%) |
| Dec 1999 | -$20.40 M(+114.7%) | $200.00 K(-104.8%) | -$21.20 M(-20.6%) |
| Sept 1999 | - | -$4.20 M(-44.0%) | -$26.70 M(+10.3%) |
| June 1999 | - | -$7.50 M(-22.7%) | -$24.20 M(+59.2%) |
| Mar 1999 | - | -$9.70 M(+83.0%) | -$15.20 M(+60.0%) |
| Dec 1998 | -$9.50 M(+2.2%) | -$5.30 M(+211.8%) | -$9.50 M(+17.3%) |
| Sept 1998 | - | -$1.70 M(-213.3%) | -$8.10 M(+24.6%) |
| June 1998 | - | $1.50 M(-137.5%) | -$6.50 M(-38.1%) |
| Mar 1998 | - | -$4.00 M(+2.6%) | -$10.50 M(+11.7%) |
| Dec 1997 | -$9.30 M(-17.0%) | -$3.90 M(+3800.0%) | -$9.40 M(+11.9%) |
| Sept 1997 | - | -$100.00 K(-96.0%) | -$8.40 M(-25.0%) |
| June 1997 | - | -$2.50 M(-13.8%) | -$11.20 M(+2.8%) |
| Mar 1997 | - | -$2.90 M(0.0%) | -$10.90 M(-2.7%) |
| Dec 1996 | -$11.20 M(+558.8%) | -$2.90 M(0.0%) | -$11.20 M(+15.5%) |
| Sept 1996 | - | -$2.90 M(+31.8%) | -$9.70 M(+27.6%) |
| June 1996 | - | -$2.20 M(-31.3%) | -$7.60 M(+46.2%) |
| Mar 1996 | - | -$3.20 M(+128.6%) | -$5.20 M(+108.0%) |
| Dec 1995 | -$1.70 M(-93.2%) | -$1.40 M(+75.0%) | -$2.50 M(-50.0%) |
| Sept 1995 | - | -$800.00 K(-500.0%) | -$5.00 M(-26.5%) |
| June 1995 | - | $200.00 K(-140.0%) | -$6.80 M(-57.5%) |
| Mar 1995 | - | -$500.00 K(-87.2%) | -$16.00 M(-36.0%) |
| Dec 1994 | -$25.00 M(-30.0%) | -$3.90 M(+50.0%) | -$25.00 M(-20.4%) |
| Sept 1994 | - | -$2.60 M(-71.1%) | -$31.40 M(-15.8%) |
| June 1994 | - | -$9.00 M(-5.3%) | -$37.30 M(-0.3%) |
| Mar 1994 | - | -$9.50 M(-7.8%) | -$37.40 M(+2.7%) |
| Dec 1993 | -$35.70 M(+119.0%) | -$10.30 M(+21.2%) | -$36.40 M(+15.2%) |
| Sept 1993 | - | -$8.50 M(-6.6%) | -$31.60 M(+12.1%) |
| June 1993 | - | -$9.10 M(+7.1%) | -$28.20 M(+27.6%) |
| Mar 1993 | - | -$8.50 M(+54.5%) | -$22.10 M(+34.8%) |
| Dec 1992 | -$16.30 M(+85.2%) | -$5.50 M(+7.8%) | -$16.40 M(+14.7%) |
| Sept 1992 | - | -$5.10 M(+70.0%) | -$14.30 M(+24.3%) |
| June 1992 | - | -$3.00 M(+7.1%) | -$11.50 M(+11.7%) |
| Mar 1992 | - | -$2.80 M(-17.6%) | -$10.30 M(+87.3%) |
| Dec 1991 | -$8.80 M(+193.3%) | -$3.40 M(+47.8%) | -$5.50 M(-39.6%) |
| Sept 1991 | - | -$2.30 M(+27.8%) | -$9.10 M(+65.5%) |
| June 1991 | - | -$1.80 M(-190.0%) | -$5.50 M(+120.0%) |
| Mar 1991 | - | $2.00 M(-128.6%) | -$2.50 M(-24.2%) |
| Dec 1990 | -$3.00 M | -$7.00 M(-638.5%) | -$3.30 M(-189.2%) |
| Sept 1990 | - | $1.30 M(+8.3%) | $3.70 M(+54.2%) |
| June 1990 | - | $1.20 M(0.0%) | $2.40 M(+100.0%) |
| Mar 1990 | - | $1.20 M | $1.20 M |
FAQ
- What is Regeneron Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
- What is Regeneron Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Regeneron Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?
What is Regeneron Pharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of REGN is $4.69 B
What is the all time high annual EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $9.67 B
What is Regeneron Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, REGN annual earnings before interest, taxes, depreciation & amortization has changed by -$566.30 M (-10.77%)
What is Regeneron Pharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of REGN is $1.63 B
What is the all time high quarterly EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $3.84 B
What is Regeneron Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, REGN quarterly earnings before interest, taxes, depreciation & amortization has changed by +$394.50 M (+31.97%)
What is Regeneron Pharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of REGN is $5.50 B
What is the all time high TTM EBITDA for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $9.67 B
What is Regeneron Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, REGN TTM earnings before interest, taxes, depreciation & amortization has changed by +$645.30 M (+13.29%)